Evidence map›Paper›PMID 41691369›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026

Taming immune responses to AAV gene therapy by programmed in vivo Treg expansion.

Lavesh Gwalani, Mincheol Park, Alexandra B Ysasi, Mona Motwani, Robert Jackson, Jie Bu, Zhengyu Luo, John Bladon, Edith L Pfister, Christian Mueller and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lavesh GwalaniGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
Mincheol ParkGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
Alexandra B YsasiGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
Mona MotwaniGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
Robert JacksonGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
Jie BuGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
Zhengyu LuoGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
John BladonGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
Edith L PfisterGenomic Medicine Unit, Sanofi, Waltham, MA, USA.
Christian MuellerGenomic Medicine Unit, Sanofi, Waltham, MA, USA. Electronic address: gmu@sanofi.com.
Sourav R ChoudhuryGenomic Medicine Unit, Sanofi, Waltham, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adeno-associated virus (AAV) vectors are a leading gene therapy vector. However, host recognition of AAV induces cytotoxic T lymphocytes (CTLs) and loss of transgene expression over time. Expanding regulatory T cells (Tregs) could suppress such responses, prevent AAV toxicity, and promote persistence of transgene expression. Interleukin-2 (IL-2) treatment can expand Tregs, but it lacks specificity and durability. THOR-834 is a synthetic PEGylated form of IL-2 engineered for enhanced Treg specificity and with improved half-life. In mice, prophylactic use of THOR-834 expands Tregs, reduces CD8

Indexed as

DependovirusGenetic TherapyGenetic VectorsT-Lymphocytes, RegulatoryAnimalsCD8-Positive T-LymphocytesGene ExpressionGene Therapy AgentsHumansInterleukin-2MiceRatsTransgenesInterleukin-2AAVAAV immunogenicityadeno-associated viral vectorgene therapyIL-2non-human primateTreg

Identifiers

PMID41691369
PMCPMC13238942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.